Staphylococcus pasteuri

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Staphylococcus pasteuri is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, coccus bacterium. It has been detected in at least 8 gut microbiome compilation studies or metastudies. The DNA G+C content is 35%. Staphylococcus pasteuri is probably a common, although minor, coloniser of the gut. (Chesneau1993; Schleifer2011Bergey)



  • This organism has been recovered from clinical sources (vomit, blood, wound), animals, food and human faeces. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Chesneau1993); (Schleifer2011Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • urea;
  • 🧂
  • Salt tolerance:
  • tolerates 5% salt; tolerates 10% salt;
  • 🌡
  • Temperature tolerance:
  • grows at 15℃; grows at 45℃;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; maltose; sucrose; trehalose; mannitol;
  • ±
  • Strain-dependent acid from carbs:
  • D-turanose;
  • ⥅
  • Substrates assimilated or utilised:
  • fructose; glucose; sucrose; trehalose;
  • ±
  • Strain-dependent substrate utilisation:
  • maltose; mannitol;
  • Active enzymes:
  • catalase; esterase C4; esterase lipase C8; α-glucosidase; β-glucuronidase; urease;
  • ±
  • Strain-dependent active enzymes:
  • arginine dihydrolase;
    • SPECIAL FEATURES (Chesneau1993); (Schleifer2011Bergey);
    Character Response
  • ✓
  • Metabolites produced:
  • lactate;
  • ✓
  • VP test:
  • active
  • ✓
  • Haemolysis:
  • present
  • Nitrate:
  • reduction is variable
  • Pigments:
  • variable
    • RESPONSE TO ANTIBIOTICS (Chesneau1993);
    Class Active Resistant
  • Penicillins:
  • oxacillin;
  • Cephalosporins:
  • cephalothin;
  • Macrolides:
  • pristinamycin;
  • Tetracyclines:
  • minocycline; tetracycline;
  • Quinolines:
  • pefloxacin;
  • Aminoglycosides:
  • gentamicin; kanamycin; neomycin; spectinomycin; streptomycin; tobramycin;
  • Polypep/ketides:
  • rifampicin;
  • bacitracin;
  • Heterocycles:
  • chloramphenicol; fosfomycin; fusidic-acid; nitrofurantoin; trimethoprim;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • novobiocin; pristinamycin;
  • vibriostatin A 0 129;

  • Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Bacilli Order:  Bacillales Family:  Staphylococcaceae Genus:  Staphylococcus Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Coccus Pigment:  variable
    Health:  Unknown
    Source:  clinical sources (vomit, blood, wound), animals, food and human faeces
    DNA G+C(%):  35
    Low T(℃):  15(+)
    High T(℃):  45(+)
    NaCl 3-5%:  5(+)
    NaCl >6%:  10(+)
    		Aesculin:  neg Urea:  +
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg D-Arabinose:  neg Fructose:  + Glucose:  + Mannose:  neg Ribose:  neg Cellubiose:  neg Lactose:  neg Maltose:  + Sucrose:  + Trehalose:  + Turanose:  d Mannitol:  + Xylitol:  neg NAc-α-GA:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    L-Arabinose:  neg Fructose:  + Glucose:  + Mannose:  neg Ribose:  neg Xylose:  neg Cellubiose:  neg Maltose:  d Melibiose:  neg Raffinose:  neg Sucrose:  + Trehalose:  + Mannitol:  d Xylitol:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  + Urease:  + Coagulase:  neg Fibrinolysin:  neg HS nuclease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  + β-Glucosidase:  vr β-Glucuronidase:  + α-Mannosidase:  neg ArgDH:  d OrnDC:  neg LeuAA:  neg PyrrolidAA:  neg AlkalineP:  neg AcidP:  neg DNAse:  neg Esterase(C4):  + EstLip(C8):  + Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Lactate:  + Pigment:  variable
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    oxacillin:  S(5; disc)
    penicillin_G:  Var(MIC50): 6), MIC90: Var(6
    cephalothin:  S(30; disc)
    gentamicin:  S(15; disc)
    kanamycin:  S(30U)
    neomycin:  S(30U)
    spectinomycin:  S(100; disc)
    streptomycin:  S(10U)
    tobramycin:  S(10; disc)
    erythromycin:  Var(MIC50): 15U), MIC90: Var(15U
    oleandomycin:  Var(MIC50): 15U), MIC90: Var(15U
    pristinamycin:  S(20; disc)
    spiramycin:  Var(MIC50): 100; disc), MIC90: Var(100; disc
    pefloxacin:  S(5; disc)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    minocycline:  S(30U)
    tetracycline:  S(30U,vr)
    vancomycin:  S(30; disc)
    bacitracin:  R(0.4U)
    rifampicin:  S(30; disc)
    chloramphenicol:  S(30,vr)
    fosfomycin:  S(50; disc)
    nitrofurantoin:  S(300; disc)
    trimethoprim:  S(5; disc)
    lincomycin:  Var(MIC50): 15; disc), MIC90: Var(15; disc
    novobiocin:  S(5; disc)
    fusidic-acid:  S(10; disc)
    vibriostat_129:  R(500; disc)

    References

    SPECIFIC REFERENCES FOR STAPHYLOCOCCUS PASTEURI
  • Chesneau1993 - Staphylococcus pasteuri sp. nov., Isolated from Human, Animal, and Food Specimens.
  • Schleifer2011Bergey - Bergey's manual of systematic bacteriology. Vol. 3, The Firmicutes. Family Staphylococcaceae, Genus I. Staphylococcus
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR STAPHYLOCOCCUS PASTEURI
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Cassir2015 - Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates
  • Dubourg2013 - The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • McLaughlin2010 - The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing.
  • Pfleiderer2013 - Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Walker2011 - High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease.
  • ...............................
    • GENERAL REFERENCES FOR STAPHYLOCOCCUS PASTEURI
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
    • Added: April 08, 2021